The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment

For a significant proportion of patients with inflammatory bowel disease (IBD), primary non-response and secondary loss of response to treatment remain significant issues. Anti-tumor necrosis factor therapies have been licensed for use in IBD. Other disease-related pathways have been targeted as wel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jin-Woo Kim, Su-Young Kim
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	janus kinase inhibitor inflammatory bowel disease small molecule drugs Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/94e901fc212c42a2bfbcb2265d38a2d7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:94e901fc212c42a2bfbcb2265d38a2d7
record_format	dspace
spelling	oai:doaj.org-article:94e901fc212c42a2bfbcb2265d38a2d72021-11-11T16:48:31ZThe Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment10.3390/ijms2221113221422-00671661-6596https://doaj.org/article/94e901fc212c42a2bfbcb2265d38a2d72021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11322https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067For a significant proportion of patients with inflammatory bowel disease (IBD), primary non-response and secondary loss of response to treatment remain significant issues. Anti-tumor necrosis factor therapies have been licensed for use in IBD. Other disease-related pathways have been targeted as well, including the interleukin 12/23 axis and lymphocyte tracking. However, the need for parenteral administration and the associated costs of dispensing and monitoring all biologics remain a burden on healthcare systems and patients. Janus kinase inhibitors are small-molecule drugs that can be administered orally and are relatively inexpensive, thus offering an additional option for treating IBD. They have been shown to be effective in patients with ulcerative colitis (UC), but they are less effective in those with Crohn’s disease (CD). Nonetheless, given the immune-system-based mechanism of these drugs, their safety profile remains a cause for concern. This article provides an overview of Janus kinase (JAK) inhibitors and new trends in the treatment of IBD.Jin-Woo KimSu-Young KimMDPI AGarticlejanus kinase inhibitorinflammatory bowel diseasesmall molecule drugsBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11322, p 11322 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	janus kinase inhibitor inflammatory bowel disease small molecule drugs Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	janus kinase inhibitor inflammatory bowel disease small molecule drugs Biology (General) QH301-705.5 Chemistry QD1-999 Jin-Woo Kim Su-Young Kim The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
description	For a significant proportion of patients with inflammatory bowel disease (IBD), primary non-response and secondary loss of response to treatment remain significant issues. Anti-tumor necrosis factor therapies have been licensed for use in IBD. Other disease-related pathways have been targeted as well, including the interleukin 12/23 axis and lymphocyte tracking. However, the need for parenteral administration and the associated costs of dispensing and monitoring all biologics remain a burden on healthcare systems and patients. Janus kinase inhibitors are small-molecule drugs that can be administered orally and are relatively inexpensive, thus offering an additional option for treating IBD. They have been shown to be effective in patients with ulcerative colitis (UC), but they are less effective in those with Crohn’s disease (CD). Nonetheless, given the immune-system-based mechanism of these drugs, their safety profile remains a cause for concern. This article provides an overview of Janus kinase (JAK) inhibitors and new trends in the treatment of IBD.
format	article
author	Jin-Woo Kim Su-Young Kim
author_facet	Jin-Woo Kim Su-Young Kim
author_sort	Jin-Woo Kim
title	The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
title_short	The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
title_full	The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
title_fullStr	The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
title_full_unstemmed	The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
title_sort	era of janus kinase inhibitors for inflammatory bowel disease treatment
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/94e901fc212c42a2bfbcb2265d38a2d7
work_keys_str_mv	AT jinwookim theeraofjanuskinaseinhibitorsforinflammatoryboweldiseasetreatment AT suyoungkim theeraofjanuskinaseinhibitorsforinflammatoryboweldiseasetreatment AT jinwookim eraofjanuskinaseinhibitorsforinflammatoryboweldiseasetreatment AT suyoungkim eraofjanuskinaseinhibitorsforinflammatoryboweldiseasetreatment
_version_	1718432253141319680

The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment

Ejemplares similares